4//SEC Filing
Freedman Edward D. 4
Accession 0000899243-20-019854
CIK 0001807901other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:28 PM ET
Size
14.9 KB
Accession
0000899243-20-019854
Insider Transaction Report
Form 4
Freedman Edward D.
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2020-07-17+53,131→ 53,131 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (53,131 underlying) - Award
Stock Option (right to buy)
2020-07-17+660→ 660 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (660 underlying) - Conversion
Series B Preferred Stock
2020-07-21−11,974→ 0 total→ Common Stock (2,348 underlying) - Conversion
Common Stock
2020-07-21+2,348→ 54,461 total - Award
Stock Option (right to buy)
2020-07-17+2,112→ 2,112 totalExercise: $18.00Exp: 2030-07-16→ Common Stock (2,112 underlying)
Footnotes (4)
- [F1]The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on October 1, 2020, with the remainder of the shares vesting in equal monthly installments following October 1, 2020 through October 1, 2023, subject to the reporting person's continued service on each applicable vesting date.
- [F3]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 29, 2021, with the remainder of the shares vesting in equal monthly installments following May 29, 2021 through May 29, 2024, subject to the reporting person's continued service on each applicable vesting date.
- [F4]This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
Documents
Issuer
Pandion Therapeutics, Inc.
CIK 0001807901
Entity typeother
Related Parties
1- filerCIK 0001817434
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 7:28 PM ET
- Size
- 14.9 KB